Updates in the Treatment of Advanced/Recurrent Endometrial Cancer: Data from the NRG-GY018 Study

Video

Ramez Eskander, MD, presents data from the GY018 study investigating pembrolizumab versus placebo in addition to carboplatin/paclitaxel in patients with advanced/recurrent endometrial cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
      Real-World Data Support Dostarlimab Combo Benefit in RUBY Trial
      A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
      ctDNA Data in Gynecologic Cancer RT Population May Be Hypothesis-Generating
      ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
      ctDNA Clearance Confers Responses to Radiation in Gynecologic Malignancies
      Investigators evaluated ctDNA as a potentially noninvasive method to predict response to radiotherapy among those with gynecologic malignancies.
      Assessing ctDNA as a Predictor of RT Responses in Gynecologic Cancers
      The Foundation for Women’s Cancer provides multicultural resources for patients with gynecologic cancers to help address gaps in care.
      Overcoming Barriers to Trial Enrollment and Gaps in Gynecologic Cancer Care
      Ginger J. Gardner, MD, FACOG, addresses the growing uterine cancer cases among patients in the United States and the need for greater genetic testing.
      Advancing Prevention and Genetic Testing Methods in Uterine Cancer
      Ginger J. Gardner, MD, FACOG, discussed the state of gynecologic cancers and her role in empowering research, education, and awareness surrounding them.
      Raising Awareness to Address the Rising Incidence of Gynecologic Cancers
      Fertility Preservation Rates May Increase With Uterine Transposition in Pelvic Cancers
      Fertility Preservation Rates May Increase With Uterine Transposition in Pelvic Cancers
      Uterine Transposition Aims to Preserve Fertility During Radiation
      Uterine Transposition Aims to Preserve Fertility During Radiation
      Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
      ADCs May “Change the World” in Gynecologic Cancer Management
      Related Content
      More than 80% of patients who were screened for cervical cancer and provided with a self-collection kit did so by utilizing the kit.

      Self-Collection May Help Increase Cervical Cancer Screening Rates

      Roman Fabbricatore
      June 14th 2025
      Article

      More than 80% of patients who were screened for cervical cancer and provided with a self-collection kit did so by utilizing the kit.

      Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

      Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

      Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
      May 26th 2025
      Podcast

      Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

      Less radical surgery did not come at the expense of postoperative metrics, including 30-day readmissions, surgical findings, or receipt of adjuvant therapy.

      Simple vs Radical Hysterectomy Shows Comparable Survival in Cervical Cancer

      Roman Fabbricatore
      May 27th 2025
      Article

      Less radical surgery did not come at the expense of postoperative metrics, including 30-day readmissions, surgical findings, or receipt of adjuvant therapy.

      Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

      Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

      Kathleen N. Moore, MD, MS
      March 17th 2025
      Podcast

      Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

      Certain subpopulations experienced significantly poorer outcomes in 2020, highlighting concerns regarding access to care.

      Vulvar Cancer Survival Discrepancies Seen in Year 1 of COVID-19 Pandemic

      Roman Fabbricatore
      March 19th 2025
      Article

      Certain subpopulations experienced significantly poorer outcomes in 2020, highlighting concerns regarding access to care.

      Socioeconomic or racial disparities may contribute to unchanged overall survival among certain patients with metastatic uterine cancer.

      Uterine Cancer Survival Rates Have Improved Despite Higher Mortality Risks

      Russ Conroy
      March 18th 2025
      Article

      Socioeconomic or racial disparities may contribute to unchanged overall survival among certain patients with metastatic uterine cancer.